Sidley provided counsel to Celsion Corporation, an oncology drug development company, on its acquisition of EGEN, Inc. for up to $44 million in cash and stock. EGEN is a clinical stage biopharmaceutical company focused on developing therapeutics for cancer and other difficult to treat diseases. The deal team was led by Sidley partner Sam Zucker, who resides in the firm’s Palo Alto office.